Cat. No. 0542
Chemical Name: (±)-1-(5-Isoquinolinesulphonyl)-2-me
Biological ActivityProtein kinase inhibitor. IC50 values for inhibition of PKC, PKG, PKA and myosin light chain kinase are 6.0, 5.8, 3.0 and 97.0 μM respectively.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Quick et al (1992) The structure and biological activities of the widely used protein kinase inhibitor, H7, differ depending on the commercial source. Biochem.Biophys.Res.Commun. 187 657. PMID: 1530632.
Ratz et al (1990) Effect of the kinase inhibitor, H-7, on stress, crossbridge phosphorylation, muscle shortening and inositol phosphate production in rabbit arteries. J.Pharmacol.Exp.Ther. 252 253. PMID: 2299593.
Hidaka et al (1984) Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 23 5036. PMID: 6238627.
If you know of a relevant reference for H-7 dihydrochloride please let us know.
Citations are publications that use Tocris products. Selected citations for H-7 dihydrochloride include:
Barcomb et al (2013) Enzymatic activity of CaMKII is not required for its interaction with the glutamate receptor subunit GluN2B. Front Mol Neurosci 84 834. PMID: 24056996.
Belmeguenai and Hansel (2005) A role for protein phosphatases 1, 2A, and 2B in cerebellar long-term potentiation. Mol Pharmacol 25 10768. PMID: 16291950.
Do you know of a great paper that uses H-7 dihydrochloride from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: H-7 dihydrochloride, supplier, Protein, kinase, Broad, Spectrum, inhibitors, inhibits, Tocris Bioscience, Broad Spectrum Protein Kinase Inhibitor Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent Syk kinase inhibitor; also inhibits assembly of NLRP3 inflammasomesSTK16-IN-1
Serine/threonine protein kinase 16 (STK16) inhibitor; also inhibits P13Kδ, P13Kγ and mTOR kinases.AZ PFKFB3 26
Potent and selective PFKFB3 inhibitorNCL 00017509
Potent and reversible NIMA related kinase 2 (Nek2) inhibitorXMD 8-87
Potent Ack1/TNK2 inhibitorSKI 178
Non-lipid sphingosine kinase 1 (SphK1) inhibitorML 315 hydrochloride
Inhibitor of Clk and DYRK kinasesEverolimus
mTOR inhibitor;immunosuppressantPKI (5-24)
High affinity PKA inhibitorTDZD 8
Selective non-ATP competitive inhibitor of GSK 3βBI 605906
Selective IKKβ inhibitorGSK 319347A
Potent and selective IKKε inhibitorFRAX 597
Potent group I PAK inhibitorMRT 68921 dihydrochloride
Potent ULK inhibitor; inhibits autophagyAM 2394
Potent glucokinase activator; orally bioavailableeCF 309
Potent mTOR inhibitorPF 3758309 dihydrochloride
Potent PAK4 inhibitor; orally availableAZ Dyrk1B 33
Potent and selective Dyrk1B kinase inhibitorPF 06409577
Potent and selective allosteric activator of AMPKPerifosine
PKB/Akt inhibitor; also modulates Kv2.1 currentRAF 265
Raf kinase and VEGFR-2 inhibitorCZC 25146
Potent LRRK2 inhibitorRo 3280
Potent and selective PLK1 inhibitorRMM 46
MSK/RSK family kinase inhibitor
June 14 - 17, 2017
Boston, MA, USA